USFDA completes inspection of Nagpur facility, no observation issued: Lupin
New Delhi: Drug firm Lupin said the US health regulator has completed an inspection of its Nagpur facility in Maharashtra without any observation. The product-specific pre-approval inspection by USFDA concluded without any observation, Lupin said in a BSE filing.
Read Also:Lupin gets EIR from USFDA for Nagpur facility
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd